DE69004924D1 - Therapeutische verwendung von 5-ht3-rezeptor-antagonisten. - Google Patents

Therapeutische verwendung von 5-ht3-rezeptor-antagonisten.

Info

Publication number
DE69004924D1
DE69004924D1 DE90905482T DE69004924T DE69004924D1 DE 69004924 D1 DE69004924 D1 DE 69004924D1 DE 90905482 T DE90905482 T DE 90905482T DE 69004924 T DE69004924 T DE 69004924T DE 69004924 D1 DE69004924 D1 DE 69004924D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
therapeutic use
disorders
agoraphobia
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE90905482T
Other languages
English (en)
Other versions
DE69004924T2 (de
Inventor
Alberto Azcona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Sandoz Patent GmbH
Original Assignee
Sandoz AG
Sandoz Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898909147A external-priority patent/GB8909147D0/en
Priority claimed from GB898916602A external-priority patent/GB8916602D0/en
Application filed by Sandoz AG, Sandoz Patent GmbH filed Critical Sandoz AG
Publication of DE69004924D1 publication Critical patent/DE69004924D1/de
Application granted granted Critical
Publication of DE69004924T2 publication Critical patent/DE69004924T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69004924T 1989-04-21 1990-04-06 Therapeutische verwendung von 5-ht3-rezeptor-antagonisten. Expired - Fee Related DE69004924T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898909147A GB8909147D0 (en) 1989-04-21 1989-04-21 Improvements in or relating to organic compounds
GB898916602A GB8916602D0 (en) 1989-07-20 1989-07-20 Improvements in or relating to organic compounds
PCT/EP1990/000540 WO1990012569A1 (en) 1989-04-21 1990-04-06 Therapeutic use of 5-ht3 receptor antagonists

Publications (2)

Publication Number Publication Date
DE69004924D1 true DE69004924D1 (de) 1994-01-13
DE69004924T2 DE69004924T2 (de) 1994-05-19

Family

ID=26295258

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69004924T Expired - Fee Related DE69004924T2 (de) 1989-04-21 1990-04-06 Therapeutische verwendung von 5-ht3-rezeptor-antagonisten.

Country Status (10)

Country Link
EP (1) EP0422154B1 (de)
JP (1) JPH0669963B2 (de)
KR (1) KR920700034A (de)
AT (1) ATE97803T1 (de)
AU (1) AU631632B2 (de)
CA (1) CA2031214A1 (de)
DE (1) DE69004924T2 (de)
DK (1) DK0422154T3 (de)
ES (1) ES2061024T3 (de)
WO (1) WO1990012569A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276050A (en) * 1989-08-01 1994-01-04 Glaxo Group Limited Medicaments
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5508287A (en) * 1992-02-24 1996-04-16 Merrell Pharmaceuticals Inc. 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist
AU4081393A (en) * 1992-05-23 1993-12-30 Smithkline Beecham Plc Medicaments for the treatment of anxiety
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
JP5387648B2 (ja) 2011-10-14 2014-01-15 株式会社デンソー 指針表示装置

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1365296A (en) * 1970-10-30 1974-08-29 Unilever Ltd Dentifrice compositions
EP0099194A3 (de) * 1982-07-03 1984-04-11 Beecham Group Plc Benzamide
KR920003064B1 (ko) * 1984-01-25 1992-04-13 글락소 그룹 리미티드 헤테로시클릭 화합물의 제조방법
AU583343B2 (en) 1985-01-23 1989-04-27 Glaxo Group Limited Heterocyclic compounds
EP0405617A3 (en) * 1985-03-14 1992-11-25 Beecham Group P.L.C. Medicaments for the treatment of anxiety
GB8518743D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
GB8518745D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
GB8518741D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Process
EP0212398A2 (de) 1985-08-21 1987-03-04 Siemens Aktiengesellschaft Verfahren zur Erkennung von Mehrfrequenzcodesignalen mit überlagerten Störsignalen
IL80707A (en) 1985-12-23 1991-03-10 Hughes Aircraft Co Gaseous discharge device simmering circuit
DK134687A (da) 1986-03-17 1987-09-18 Glaxo Group Ltd Indolderivater
GB8701494D0 (en) 1987-01-23 1987-02-25 Glaxo Group Ltd Chemical compounds
GB8617994D0 (en) 1986-07-23 1986-08-28 Glaxo Group Ltd Heterocyclic compounds
EP0254584B1 (de) * 1986-07-25 1992-10-07 Beecham Group Plc Azabicyclische Verbindungen, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
HU202108B (en) 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
GB8623819D0 (en) 1986-10-03 1986-11-05 Glaxo Group Ltd Heterocyclic compounds
ES2036587T5 (es) 1986-11-21 1995-10-16 Glaxo Group Ltd Medicamentos para el tratamiento o prevencion del sindrome de abstinencia.
GR871809B (en) 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
ES2051753T3 (es) * 1986-12-16 1994-07-01 Robins Co Inc A H N-(1-azabiciclo(2.2.2)octo-3-il) benzamidas y tiobenzamidas ansioliticas.
GB8806990D0 (en) 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
US4918080A (en) 1987-04-14 1990-04-17 Glaxo Group Limited Imidazollyl containing ketone derivatives
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
IE61669B1 (en) 1987-09-03 1994-11-16 Glaxo Group Ltd Lactam derivatives
GB8720693D0 (en) 1987-09-03 1987-10-07 Glaxo Group Ltd Chemical compounds
GB8720805D0 (en) * 1987-09-04 1987-10-14 Naylor R J 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
EP0317088A1 (de) 1987-10-22 1989-05-24 Glaxo Group Limited Ketonderivate
DE3740984A1 (de) * 1987-12-03 1989-06-15 Sandoz Ag N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
GB8802127D0 (en) 1988-02-01 1988-03-02 Glaxo Group Ltd Chemical compounds
EP0329932B1 (de) * 1988-02-23 1995-10-18 Merrell Pharmaceuticals Inc. Verwendung von Chinolizin- und Chinolizinon-Derivaten zur Herstellung von Arzneimitteln
EP0329904A1 (de) * 1988-02-23 1989-08-30 Merrell Dow Pharmaceuticals Inc. Verwendung von Chinolizin- und Chinolizinon-Derivaten zur Herstellung von Arzneimitteln zur Behandlung von Anxietas
JPH0249772A (ja) 1988-04-07 1990-02-20 Glaxo Group Ltd イミダゾール誘導体
US4863921A (en) 1988-04-27 1989-09-05 Rorer Pharmaceutical Corporation Dibenzofurancarboxamides and their pharmaceutical compositions and methods
EP0339959A3 (de) 1988-04-27 1991-03-20 Glaxo Group Limited Laktam-Derivate
GB8812636D0 (en) 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
GB8814277D0 (en) 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
DK0422154T3 (da) 1994-03-07
AU5415890A (en) 1990-11-16
CA2031214A1 (en) 1990-10-22
ATE97803T1 (de) 1993-12-15
ES2061024T3 (es) 1994-12-01
JPH03505881A (ja) 1991-12-19
EP0422154B1 (de) 1993-12-01
WO1990012569A1 (en) 1990-11-01
JPH0669963B2 (ja) 1994-09-07
DE69004924T2 (de) 1994-05-19
EP0422154A1 (de) 1991-04-17
KR920700034A (ko) 1992-02-19
AU631632B2 (en) 1992-12-03

Similar Documents

Publication Publication Date Title
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
IT1232889B (it) Composizioni e procedimento per il trattamento ammorbidente di tessuti
DE69834693D1 (de) Zusammensetzung zur behandlung von elastischen polyurethanfasern und die damit behandelten fasern
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
ATE209909T1 (de) Verwendung von tachykinin-antagonisten zur behandlung von erbrechen
DE69526935T2 (de) Verwendung von mycobacterium zur tumorbehandlung
DE69712578T2 (de) Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE227278T1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE69004924D1 (de) Therapeutische verwendung von 5-ht3-rezeptor-antagonisten.
DE69131398T2 (de) Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall
DE69007486T2 (de) Verwendung von calciumantagonisten für die behandlung von narben.
DE423591T1 (de) Vorrichtung zum kontrollierten und unabhaengigen verschwenken von richt- und biegeplattformen.
DE69010172D1 (de) Verfahren zur Vermögenserhöhung von elektroakustischen Tieffrequenzwandlern und damit übereinstimmende Wandler.
DE69619051D1 (de) Behandlung von Füllstoffen mit Oxasilacycloalkanen
DE58902451D1 (de) (s)-emopamil zur anwendung bei der behandlung von migraene.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
DE59711240D1 (de) Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
DE68929177T2 (de) Verwendung von Dihydropyridinen zur Vorbeugung und Behandlung cerebraler Durchblutungsstörungen
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DE295827T1 (de) Verwendung von 24,25-dihydroxycholecalciferol bei der heilung von knochenbruechen.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee